(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 2.96% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Becton Dickinson & Co's revenue in 2026 is $21,840,000,000.On average, 17 Wall Street analysts forecast BDX's revenue for 2026 to be $6,430,479,954,030, with the lowest BDX revenue forecast at $5,622,745,454,700, and the highest BDX revenue forecast at $6,781,544,771,760. On average, 17 Wall Street analysts forecast BDX's revenue for 2027 to be $6,630,843,776,832, with the lowest BDX revenue forecast at $5,632,164,266,883, and the highest BDX revenue forecast at $7,108,349,012,655.
In 2028, BDX is forecast to generate $6,793,532,350,902 in revenue, with the lowest revenue forecast at $5,871,630,431,172 and the highest revenue forecast at $7,234,789,430,748.